[HTML][HTML] Therapeutics for COVID-19 and post COVID-19 complications: An update

D Basu, VP Chavda, AA Mehta - Current Research in Pharmacology and …, 2022 - Elsevier
Since its inception in late December 2020 in China, novel coronavirus has affected the
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …

In vitro and in vivo models for studying SARS-CoV-2, the etiological agent responsible for COVID-19 pandemic

RB Rosa, WM Dantas, JCF do Nascimento… - Viruses, 2021 - mdpi.com
The emergence and rapid worldwide spread of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has prompted the scientific community to rapidly develop in …

Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin

GD de Melo, F Lazarini, F Larrous, L Feige… - EMBO molecular …, 2021 - embopress.org
The devastating pandemic due to SARS‐CoV‐2 and the emergence of antigenic variants
that jeopardize the efficacy of current vaccines create an urgent need for a comprehensive …

[HTML][HTML] Identification of novel inhibitors for SARS-CoV-2 as therapeutic options using machine learning-based virtual screening, molecular docking and MD …

A Samad, A Ajmal, A Mahmood, B Khurshid… - Frontiers in Molecular …, 2023 - frontiersin.org
The new coronavirus SARS-COV-2, which emerged in late 2019 from Wuhan city of China
was regarded as causing agent of the COVID-19 pandemic. The primary protease which is …

[HTML][HTML] Repositioning Ivermectin for COVID-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication

ZY Low, AJW Yip, SK Lal - Biochimica et Biophysica Acta (BBA)-Molecular …, 2022 - Elsevier
Ivermectin (IVM) is an FDA approved macrocyclic lactone compound traditionally used to
treat parasitic infestations and has shown to have antiviral potential from previous in-vitro …

[HTML][HTML] Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in Lebanon

AA Samaha, H Mouawia, M Fawaz, H Hassan… - Viruses, 2021 - ncbi.nlm.nih.gov
Objective: This study was designed to determine the efficacy of ivermectin, an FDA-
approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 …

COVID-19–associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis

A Bhattacharyya, P Sarma, H Kaur… - Indian Journal of …, 2021 - journals.lww.com
BACKGROUND: Till now, no meta-analysis is available to address the clinical profile, risk
factors, different interventions, and outcomes among COVID-19–associated rhino-orbito …

Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis

F Jiang, Y Liu, Y Xue, P Cheng, J Wang, J Lian… - International …, 2023 - Elsevier
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
monkeypox virus (MPXV) severely threaten human health; however, currently, no vaccine …

Use of antimicrobials among suspected COVID-19 patients at selected hospitals, Bangladesh: findings from the first wave of COVID-19 pandemic

S Mah-E-Muneer, MZ Hassan, MAAJ Biswas… - Antibiotics, 2021 - mdpi.com
Antimicrobials are empirically used in COVID-19 patients resulting in increased
antimicrobial resistance. Our objective was to assess antimicrobial use among suspected …

Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects

SP Rendic - Archives of Toxicology, 2021 - Springer
The review presents metabolic properties of Ivermectin (IVM) as substrate and inhibitor of
human P450 (P450, CYP) enzymes and drug transporters. IVM is metabolized, both in vivo …